Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Liraglutide: Evidence Summary
Evidence summary for Liraglutide across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Liraglutide overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Type 2 diabetes (glycemic control) | Tier A | 100 | Multiple Phase 3 RCTs (LEAD program) demonstrate 1.1-1.4% HbA1c reduction |
| Chronic weight management | Tier A | 10 | SCALE trial showed 8.4% weight loss; FDA-approved indication |
| Cardiovascular risk reduction | Tier A | 1 | LEADER CVOT (n=9,340) showed 13% MACE risk reduction |
| NASH/NAFLD | Tier B | 5 | Moderate RCT evidence for liver fat reduction |
References (12)
- Liraglutide vs glimepiride monotherapy for type 2 diabetes (LEAD-1) — Marre M, Shaw J, Brändle M, et al. . Diabetes Care (2009) PMID: 19317822
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE) — Pi-Sunyer X, Astrup A, Fujioka K, et al. . New England Journal of Medicine (2015) PMID: 26132939
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) — Marso SP, Daniels GH, Tanaka K, et al. . New England Journal of Medicine (2016) PMID: 27295427
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity — Kelly AS, Auerbach P, Barrientos-Perez M, et al. . New England Journal of Medicine (2020) PMID: 32233338
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist. — Bode B . The American journal of managed care (2011) PMID: 21517658
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. — Davies MJ, Bergenstal R, Bode B, et al. . JAMA (2015) PMID: 26284720
- Liraglutide for weight management: a critical review of the evidence. — Mehta A, Marso SP, Neeland IJ . Obesity science & practice (2017) PMID: 28392927
- Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis. — Konwar M, Bose D, Jaiswal SK, et al. . International journal of clinical practice (2022) PMID: 35936066
- Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. — Xie Z, Yang S, Deng W, et al. . Clinical epidemiology (2022) PMID: 36510488
- GLP-1 receptor agonists: A review of glycemic benefits and beyond. — Clark L . JAAPA : official journal of the American Academy of Physician Assistants (2024) PMID: 38531038
- Long-term weight outcomes in patients treated with liraglutide 3.0 mg in real-world clinical practice. — Grannell A, Al-Najim W, le Roux C . Clinical obesity (2024) PMID: 37615384
- The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism. — Andreozzi F, Raciti GA, Nigro C, et al. . Journal of translational medicine (2016) PMID: 27473212